Zymeworks Inc. (NASDAQ: ZYME) is a Healthcare company (Biotechnology) with a market capitalization of $1.8B. The Maz Rating grades it against the other companies in its sector.
Zymeworks Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $25.84, Zymeworks Inc. trades at 38.3x trailing earnings, 6.7x sales and 7.1x book value, with an EV/EBITDA of 41.1. Over the last twelve months it generated about $268M of revenue and $47M of net income. It runs a gross margin of 98.3%, an operating margin of 16.6% and a net margin of 16.3%. It shows return on equity of 22.5%, return on invested capital of 4.3% and a free cash flow yield of -6.2%. On the balance sheet: a debt-to-equity ratio of 2.52 and a current ratio of 3.30. Over the past 52 weeks the share price ranged from $21.52 to $31.97, with a beta of 1.17.
Zymeworks Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 21 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.